Select Page

Investor Information

At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.

Disclosure Under Regulation 30

ParticularsDate
Intimation about Acquisition (Surgimatix)February 20, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory OrderFebruary 12, 2024
Sun Pharma included in S&P Global Sustainability Yearbook 2024February 12, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Subsidiary Company named Sun Pharma Middle East FZ-LLCFebruary 6, 2024
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Subsidiary CompanyFebruary 5, 2024
Intimation of Schedule of Analyst/Institutional Investor MeetingFebruary 5, 2024
Stock Exchange Letter Disclosure of Q3FY24 Earnings Call Audio RecordingJanuary 31, 2024
Sun Pharma (together with its subsidiaries and/or affiliates”) have entered into a definitive merger agreement with Taro Pharmaceutical Industries Ltd (TARO) to acquire all of the outstanding ordinary shares of Taro not currently held by Sun Pharma.January 18, 2024
Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in IndiaJanuary 17, 2024
Intimation regarding WOS receiving order of statutory authority under the Goods and Services Tax Act, 2017January 11, 2024
Intimation regarding orders passed by statutory authority under the Goods and Services Tax Act, 2017January 3, 2024
Intimation of acquisition of Libra Merger LimitedJanuary 2, 2024
Intimation of agreement to acquire stake in Lyndra Therapeutics, IncDecember 18, 2023
General update - Inclusion of specialty product ILUMETRI, (Tildrakizumab Injection) in category B of China’s National Reimbursement Drug ListDecember 13, 2023
Update – Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries LtdDecember 12, 2023
Intimation of Changes in Senior Management PersonnelDecember 7, 2023
Licensing Agreement with Aclaris Therapeutics, IncDecember 6, 2023
Closure of Sun Pharma ESOP TrustDecember 5, 2023
Response to BSE query on Volume movementDecember 4, 2023
Intimation of Schedule of Analyst/ Institutional Investor MeetingNovember 16, 2023
Stock Exchange Letter Disclosure of Q2FY24 Earnings Call Audio RecordingNovember 01, 2023
Licensing Agreement with Zydus for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in IndiaOctober 30, 2023
Sustainability Report 2022-23October 19, 2023
Nidlegy Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanomaOctober 16, 2023
Agreement to acquire minority stake in Ezerx Health Tech Private Limited and Agatsa Software Private LimitedOctober 5, 2023
Disclosure of binding letter of intent to acquire the balance 25% outstanding shares of Sun Pharma de México, S.A. de C.V.September 28, 2023
Intimation of Schedule of Analyst/Institutional Investor MeetingSeptember 18, 2023
Submission of ESG Overview for financial year 2022-23 of Sun Pharmaceutical Industries LimitedAugust 29, 2023
Voting Results of 31st Annual General Meeting of the CompanyAugust 29, 2023
Outcome and Proceedings of 31st Annual General Meeting of the CompanyAugust 28, 2023
Speech delivered by Mr. Dilip Shanghvi, Managing Director, at the 31st Annual General Meeting of the CompanyAugust 28, 2023
Intimation of Schedule of Analyst/ Institutional Investor MeetingAugust 24, 2023
Intimation of Schedule of Analyst/Institutional Investor MeetingAugust 16, 2023
Disclosure - Details of Agreement (Articles of Association of the Company)August 14, 2023
Disclosure - Details of LitigationAugust 14, 2023
Intimation of Schedule of Analyst/Institutional Investor MeetingAugust 4, 2023
Stock Exchange Letter Disclosure of Q1FY24 Earnings Call Audio RecordingAugust 3, 2023
Intimation of merger of entities in which the Company owns stake through its subsidiaryJuly 20, 2023
Intimation of 31st Annual General Meeting and Record date for final dividend FY2022-23July 7, 2023
Sun Pharma Presents Data from First in Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific SessionsJune 24, 2023
Sun Pharma Announces Health Canada Approval of WINLEVI (clascoterone cream 1%) for Topical Treatment of AcneJune 19, 2023
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingMay 30, 2023
Sun Pharma Announces China NMPA Approval For ILUMETRI (Tildrakizumab Injection) For Treatment Of Adults with Moderate-To-Severe Plaque PsoriasisMay 30, 2023
Sun Pharma and Philogen enter into an Exclusive Distribution, License and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New ZealandMay 30, 2023
Update relating to earnings callMay 27, 2023
Non-binding indication of interest to acquire shares of Taro Pharmaceutical Industries Ltd., IsraelMay 27, 2023
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingMay 27, 2023
Appointment of DirectorsMay 27, 2023
Stock Exchange Letter Disclosure of Q4FY23 Earnings Call Audio RecordingMay 26, 2023
Deuruxolitinib (CTP-543) Clinical Program UpdateMay 2, 2023
Sun Pharma launches CEQUA®, a novel therapy for Dry Eye Disease in IndiaApril 25, 2023
Update on US FDA Inspection at Mohali FacilityApril 23, 2023
ParticularsDate
Update on IT Security IncidentMarch 26, 2023
Acquisition of majority stake in Vivaldis Health And Foods Private LimitedMarch 24, 2023
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b StudyMarch 22, 2023
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia AreataMarch 18, 2023
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingMarch 14, 2023
Sun Pharma completes acquisition of Concert PharmaceuticalsMarch 06, 2023
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingMarch 06, 2023
Intimation of IT Security IncidentMarch 2, 2023
Acquiring minority stake in Agatsa and RemidioFebruary 18, 2023
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingFebruary 03, 2023
Stock Exchange Letter Disclosure of Earnings Call Audio RecordingFebruary 01, 2023
Outcome of Q3 Board MeetingJanuary 31, 2023
Agreement to Acquire Concert Pharmaceuticals Inc.January 19, 2023
Sun Pharma to Acquire Concert Pharmaceuticals IncJanuary 19, 2023
Sustainability Report 2021-22December 23, 2022
Update on Mohali facility - OAI StatusDecember 08, 2022
Update on Halol FacilityDecember 08, 2022
Update on US FDA Inspection at Mohali FacilityNovember 08, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingNovember 08, 2022
Outcome of Board MeetingNovember 01, 2022
Stock Exchange Letter Disclosure of Earnings Call Audio RecordingNovember 01, 2022
Update on Acquisition of UractivTM PortfolioSeptember 28, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingSeptember 17, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingSeptember 03, 2022
Proceedings of 30th AGM and intimation of Change in the Board of DirectorsAugust 29, 2022
Chairman’s Speech at 30th AGM of the CompanyAugust 29, 2022
Update on US FDA Inspection at Mohali FacilityAugust 13, 2022
Update on US FDA Inspection at Halol facilityAugust 13, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingAugust 11, 2022
Retirement of ChairmanAugust 03, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingJune 2, 2022
Cessation of Compliance OfficerMay 31, 2022
Approval of Scheme of AmalgamationMay 30, 2022
Appointment of Lead Independent Director/ Re-appointment of DirectorsMay 30, 2022
Stock Exchange Letter Intimation of Schedule of Analyst / Institutional Investor MeetingMay 24, 2022
Top